Date Release
December 15

U.S. FDA Accepts for Review Supplemental New Drug Application for Deltoid Administration of ABILIFY MAINTENA® (aripiprazole) Extended-Release Injectable Suspension

December 10 Otsuka and Lundbeck’s brexpiprazole Demonstrates Statistically Significant Effects in New Phase III Studies in Adult Patients with Schizophrenia Presented at the American College of Neuropsychopharmacology Annual Meeting
December 9

Otsuka and Lundbeck Present Phase III Data on brexpiprazole as Adjunctive Therapy in Adult Patients with Major Depression at the American College of Neuropsychopharmacology Annual Meeting

December 8

New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy

December 8

Five-Year Data From SABRIL® (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting

December 6

U.S. FDA Approves the Labeling Update of ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension to Describe New Clinical Data for the Treatment of Acutely Relapsed Adults with Schizophrenia

December 2 Connect 4 Mental Health® Community Innovation Awards Honors Four Community-Based Organizations Addressing Serious Mental Illness

November 6

Lundbeck Partners with the Hereditary Disease Foundation, Pledges Five Additional Years of Support for Build Hope for Huntington’s Disease Campaign

November 3

Aripiprazole once-monthly injectable shows superior effectiveness to paliperidone palmitate once-monthly injectable on quality of life scale in patients with schizophrenia

October 24

Lundbeck Provides Update on New Drug Application for Intravenous Carbamazepine

September 29

U.S. FDA approves dual-chamber syringe for ABILIFY MAINTENA® (aripiprazole) extended-release injectable suspension for the treatment of schizophrenia

September 24

US FDA accepts Otsuka and Lundbeck's filing for review of brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression

September 2

Lundbeck Announces Availability of NORTHERA™ (droxidopa) Capsules in the U.S. for Symptomatic Neurogenic Orthostatic Hypotension

August 5

Connect 4 Mental Health® Announces 2014 Community Innovation Awards Call for Entries

June 24

Lundbeck Completes Acquisition of Chelsea Therapeutics

June 17

Results of a New Study of Brintellix® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction

June 16

New CONNECT Study Presents data on Measures of Cognitive Performance in Adult Patients Treated with Brintellix® (vortioxetine) for Major Depressive Disorder 

May 15

Lundbeck part of major advances in the understanding of Parkinson's disease

May 8

Lundbeck to acquire Chelsea Therapeutics

May 1

Caregivers of People with Schizophrenia Need Support, Not Stigma

April 30

FDA Accepts for Review Otsuka Pharmaceutical and Lundbeck’s Supplemental New Drug Application to Expand Abilify Maintena® (aripiprazole) Labeling

March 11

Results of Six-Year, Open-Label Extension Study Evaluating ONFI® (clobazam) CIV Published in Epilepsia

March 10

FDA Accepts Lundbeck Submission of New Drug Application for Intravenous Carbamazepine

February 3

Raise Your Hand to Support Rare Disease Research and Education

January 21

Takeda and Lundbeck Announce Brintellix® (vortioxetine) for the Treatment of Major Depressive Disorder in Adults is Now Available in Pharmacies



Contact Us

Sally Benjamin Young
Vice President, Public Affairs
Email: SYOU@lundbeck.com
Phone: (847) 282-5770

Matt Flesch
Director, Public Relations
Email: MFLE@lundbeck.com
Phone: (847) 282-1154

Follow us on Twitter!

Get our latest company news.
Click here

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.